Research & Education

Combined FISH and IHC Identifies Patients with Rare ALK Fusions that Respond to Crizotinib

DENVER – The combined use of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) identified non-small cell lung cancer (NSCLC) patients with rare or novel anaplastic lymphoma kinase (ALK) gene rearrangements, not otherwise identified by FISH alone, that showed response to crizotinib treatment.

Lymph Node Stage May Have Clinical Significance Among NSCLC Patients with Stage IV M1a Disease

DENVER – Analysis of a large non-small cell lung cancer (NSCLC) patient cohort with stage IV M1a disease identified lymph node staging as having clinical significance and an impact on prognosis.

Leptomeningeal Metastases Are More Common in NSCLC Patients Harboring EGFR Mutations and Respond Positively to TKI Therapy

DENVER – Leptomeningeal metastases (LM), a devastating complication and predictor of poor survival in lung cancer patients, was found to be more prevalent in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. Patients receiving tyrosine kinase inhibitors (TKIs) targeting EGFR mutations had a longer overall survival (OS) than those who did not receive TKIs, demonstrating the effectiveness of TKIs for LM therapy.

Liquid Biopsies for the Identification of EGFR Mutations and for the Prediction of Lung Cancer Recurrence

DENVER – Three manuscripts published in the recent issue of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC), explored the versatility of liquid biopsies by identifying EGFR mutations using circulating tumor DNA (ctDNA) in urine and plasma and examining circulating tumor cells (CTCs) in plasma to predict the risk of lung cancer recurrence after surgical resection. Collectively, these findings illustrate the potential and reach of liquid biopsies in both identifying patients suitable for targeted treatment as well as predicting cancer recurrence.

Nivolumab Cost-Effectiveness Improves by Selecting Non-Squamous NSCLC PD-L1+ Patients to Receive Treatment

DENVER – Nivolumab (NIV), a checkpoint inhibitor approved for all squamous and non-squamous non-small cell lung cancer (NSCLC) patients in 2015, is not cost-effective when compared to treatment with docetaxel (DOC), chemotherapy medication. However, a Swiss analysis showed the cost-effectiveness of NIV is improved when patients are treated with NIV based on PD-L1 positivity (PD-L1+), or if there is a reduction in dose or drug price.

CAP/IASLC/AMP Molecular Testing Guideline: Open Comment Period

Public Open Comment Period from June 28 to Aug. 2, 2016

Thank you for your interest in the public open comment period. The current draft recommendations are the product of an Expert Panel charged with reaffirming, updating, and revising the Molecular Testing Guideline for Selection of Lung Cancer Patients for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors Guideline from the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) published in 2013.

Pages